abaloparatide: Clinical Trials

7 trials of abaloparatide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting, 1 enrolling by invitation, 1 terminated. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Completed 3, Active not recruiting 1, Enrolling by invitation 1, Terminated 1, Withdrawn 1

Follow abaloparatide: new trials by email Literature Review of abaloparatide trials Research Report on abaloparatide

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effect of Osteoporotic Medications on Vertebral Bone Quality Score
Abaloparatide - Lumbar Degenerative Disease
Phase 2Enrolling by invitationState University of New York at Buffalo602026-06-182026-07-23
PTH Analog Type II Odontoid Fracture
Abaloparatide, Hard collar immobilization - Odontoid Fracture
Phase 2TerminatedDavid Lunardini222022-05-182024-09-19
Effect of Abaloparatide on Lumbar Disc Degeneration
Abaloparatide, Placebo - Degeneration Disc Intervertebral
Phase 2WithdrawnJohns Hopkins University2021-03-012021-04-12
Abaloparatide and Pelvic Fracture Healing
Abaloparatide 80 micrograms per Pen dose, Placebo prefilled injector pen - Fracture of Pelvis (Disorder)
Phase 2CompletedHospital for Special Surgery, New York482020-09-172024-06-14
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Abaloparatide, Placebo - Spinal Fusion
Phase 2Active not recruitingHospital for Special Surgery, New York962019-08-142026-09-28
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg) - Post Menopausal Osteoporosis
Phase 2CompletedRadius Health, Inc.2502012-09-252020-06-16
Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
teriparatide, Placebo, BA058 20 µg - Osteoporosis
Phase 2CompletedRadius Health, Inc.2222007-04-012017-10-30

Conditions studied

Osteoporosis (3)  ·  Bone Diseases, Metabolic (1)  ·  Fractures, Bone (1)  ·  Hip Fractures (1)  ·  Intervertebral Disc Degeneration (1)  ·  Low Back Pain (1)  ·  Osteoporosis, Postmenopausal (1)  ·  Pain (1)

Sponsors

Hospital for Special Surgery, New York (2)  ·  Radius Health, Inc. (2)  ·  David Lunardini (1)  ·  Johns Hopkins University (1)  ·  State University of New York at Buffalo (1)

Countries

United States (7)  ·  Denmark (1)  ·  Estonia (1)  ·  Poland (1)

Top investigators

David Lunardini, MD (1)  ·  Emily Stein, MD (1)  ·  Janet Crane, M.D. (1)  ·  Jeri W Nieves, PhD (1)  ·  Joseph Lane, MD (1)

Results publications

PMID 25393645, PMID 42618812